3.5.0.2 html 395 373 1 false 121 0 false 11 false false R1.htm 0001000 - Document - Document and Entity Information Sheet http://sppirx.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 1001000 - Statement - Condensed Consolidated Balance Sheets Sheet http://sppirx.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 1001501 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://sppirx.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 1002000 - Statement - Condensed Consolidated Statements of Operations Sheet http://sppirx.com/role/CondensedConsolidatedStatementsOfOperations Condensed Consolidated Statements of Operations Statements 4 false false R5.htm 1003000 - Statement - Condensed Consolidated Statements of Comprehensive Loss Sheet http://sppirx.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss Condensed Consolidated Statements of Comprehensive Loss Statements 5 false false R6.htm 1004000 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://sppirx.com/role/CondensedConsolidatedStatementsOfCashFlows Condensed Consolidated Statements of Cash Flows Statements 6 false false R7.htm 2101100 - Disclosure - Description of Business, Basis of Presentation, and Operating Segment Sheet http://sppirx.com/role/DescriptionOfBusinessBasisOfPresentationAndOperatingSegment Description of Business, Basis of Presentation, and Operating Segment Notes 7 false false R8.htm 2102100 - Disclosure - Use of Estimates and Summary of Significant Accounting Policies Sheet http://sppirx.com/role/UseOfEstimatesAndSummaryOfSignificantAccountingPolicies Use of Estimates and Summary of Significant Accounting Policies Notes 8 false false R9.htm 2103100 - Disclosure - Balance Sheet Account Detail Sheet http://sppirx.com/role/BalanceSheetAccountDetail Balance Sheet Account Detail Notes 9 false false R10.htm 2104100 - Disclosure - Gross-to-Net Product Sales Sheet http://sppirx.com/role/GrossToNetProductSales Gross-to-Net Product Sales Notes 10 false false R11.htm 2105100 - Disclosure - Net Product Sales by Geographic Region and Product Line, and Composition of License Fees and Service Revenue Sheet http://sppirx.com/role/NetProductSalesByGeographicRegionAndProductLineAndCompositionOfLicenseFeesAndServiceRevenue Net Product Sales by Geographic Region and Product Line, and Composition of License Fees and Service Revenue Notes 11 false false R12.htm 2106100 - Disclosure - Stock-Based Compensation Sheet http://sppirx.com/role/StockBasedCompensation Stock-Based Compensation Notes 12 false false R13.htm 2107100 - Disclosure - Net Loss Per Share Sheet http://sppirx.com/role/NetLossPerShare Net Loss Per Share Notes 13 false false R14.htm 2108100 - Disclosure - Fair Value Measurements Sheet http://sppirx.com/role/FairValueMeasurements Fair Value Measurements Notes 14 false false R15.htm 2109100 - Disclosure - Business Combinations and Contingent Consideration Sheet http://sppirx.com/role/BusinessCombinationsAndContingentConsideration Business Combinations and Contingent Consideration Notes 15 false false R16.htm 2110100 - Disclosure - Out-License of Marqibo, Zevalin, and Evolema in China Territory to CASI Sheet http://sppirx.com/role/OutLicenseOfMarqiboZevalinAndEvolemaInChinaTerritoryToCasi Out-License of Marqibo, Zevalin, and Evolema in China Territory to CASI Notes 16 false false R17.htm 2111100 - Disclosure - Out-License Of Zevalin In Certain Ex-U.S. Territories To Mundipharma Sheet http://sppirx.com/role/OutLicenseOfZevalinInCertainExUSTerritoriesToMundipharma Out-License Of Zevalin In Certain Ex-U.S. Territories To Mundipharma Notes 17 false false R18.htm 2112100 - Disclosure - Out-License Of Zevalin, Folotyn, Beleodaq, And Marqibo In Canada Territory To Servier Sheet http://sppirx.com/role/OutLicenseOfZevalinFolotynBeleodaqAndMarqiboInCanadaTerritoryToServier Out-License Of Zevalin, Folotyn, Beleodaq, And Marqibo In Canada Territory To Servier Notes 18 false false R19.htm 2113100 - Disclosure - Co-Promotion Arrangement With Eagle Pharmaceuticals Sheet http://sppirx.com/role/CoPromotionArrangementWithEaglePharmaceuticals Co-Promotion Arrangement With Eagle Pharmaceuticals Notes 19 false false R20.htm 2114100 - Disclosure - Convertible Senior Notes Notes http://sppirx.com/role/ConvertibleSeniorNotes Convertible Senior Notes Notes 20 false false R21.htm 2115100 - Disclosure - Mundipharma Agreement And Drug Development Liability Sheet http://sppirx.com/role/MundipharmaAgreementAndDrugDevelopmentLiability Mundipharma Agreement And Drug Development Liability Notes 21 false false R22.htm 2116100 - Disclosure - Commitments and Contingencies Sheet http://sppirx.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 22 false false R23.htm 2117100 - Disclosure - Income Taxes Sheet http://sppirx.com/role/IncomeTaxes Income Taxes Notes 23 false false R24.htm 2118100 - Disclosure - Stockholders' Equity Sheet http://sppirx.com/role/StockholdersEquity Stockholders' Equity Notes 24 false false R25.htm 2201201 - Disclosure - Description of Business, Basis of Presentation, and Operating Segment (Policies) Sheet http://sppirx.com/role/DescriptionOfBusinessBasisOfPresentationAndOperatingSegmentPolicies Description of Business, Basis of Presentation, and Operating Segment (Policies) Policies http://sppirx.com/role/UseOfEstimatesAndSummaryOfSignificantAccountingPolicies 25 false false R26.htm 2303301 - Disclosure - Balance Sheet Account Detail (Tables) Sheet http://sppirx.com/role/BalanceSheetAccountDetailTables Balance Sheet Account Detail (Tables) Tables http://sppirx.com/role/BalanceSheetAccountDetail 26 false false R27.htm 2304301 - Disclosure - Gross-to-Net Product Sales (Tables) Sheet http://sppirx.com/role/GrossToNetProductSalesTables Gross-to-Net Product Sales (Tables) Tables http://sppirx.com/role/GrossToNetProductSales 27 false false R28.htm 2305301 - Disclosure - Net Product Sales by Geographic Region and Product Line, and Composition of License Fees and Service Revenue (Tables) Sheet http://sppirx.com/role/NetProductSalesByGeographicRegionAndProductLineAndCompositionOfLicenseFeesAndServiceRevenueTables Net Product Sales by Geographic Region and Product Line, and Composition of License Fees and Service Revenue (Tables) Tables http://sppirx.com/role/NetProductSalesByGeographicRegionAndProductLineAndCompositionOfLicenseFeesAndServiceRevenue 28 false false R29.htm 2306301 - Disclosure - Stock-Based Compensation (Tables) Sheet http://sppirx.com/role/StockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://sppirx.com/role/StockBasedCompensation 29 false false R30.htm 2307301 - Disclosure - Net Loss Per Share (Tables) Sheet http://sppirx.com/role/NetLossPerShareTables Net Loss Per Share (Tables) Tables http://sppirx.com/role/NetLossPerShare 30 false false R31.htm 2308301 - Disclosure - Fair Value Measurements (Tables) Sheet http://sppirx.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://sppirx.com/role/FairValueMeasurements 31 false false R32.htm 2309301 - Disclosure - Business Combinations and Contingent Consideration (Tables) Sheet http://sppirx.com/role/BusinessCombinationsAndContingentConsiderationTables Business Combinations and Contingent Consideration (Tables) Tables http://sppirx.com/role/BusinessCombinationsAndContingentConsideration 32 false false R33.htm 2310301 - Disclosure - Out-License of Marqibo, Zevalin, and Evolema in China Territory to CASI (Tables) Sheet http://sppirx.com/role/OutLicenseOfMarqiboZevalinAndEvolemaInChinaTerritoryToCasiTables Out-License of Marqibo, Zevalin, and Evolema in China Territory to CASI (Tables) Tables http://sppirx.com/role/OutLicenseOfMarqiboZevalinAndEvolemaInChinaTerritoryToCasi 33 false false R34.htm 2314301 - Disclosure - Convertible Senior Notes (Tables) Notes http://sppirx.com/role/ConvertibleSeniorNotesTables Convertible Senior Notes (Tables) Tables http://sppirx.com/role/ConvertibleSeniorNotes 34 false false R35.htm 2315301 - Disclosure - Mundipharma Agreement And Drug Development Liability (Tables) Sheet http://sppirx.com/role/MundipharmaAgreementAndDrugDevelopmentLiabilityTables Mundipharma Agreement And Drug Development Liability (Tables) Tables http://sppirx.com/role/MundipharmaAgreementAndDrugDevelopmentLiability 35 false false R36.htm 2318301 - Disclosure - Stockholders' Equity (Tables) Sheet http://sppirx.com/role/StockholdersEquityTables Stockholders' Equity (Tables) Tables http://sppirx.com/role/StockholdersEquity 36 false false R37.htm 2401402 - Disclosure - Description of Business, Basis of Presentation, and Operating Segment - Additional Information (Detail) Sheet http://sppirx.com/role/DescriptionOfBusinessBasisOfPresentationAndOperatingSegmentAdditionalInformationDetail Description of Business, Basis of Presentation, and Operating Segment - Additional Information (Detail) Details 37 false false R38.htm 2402401 - Disclosure - Use of Estimates and Summary of Significant Accounting Policies - Additional Information (Detail) Sheet http://sppirx.com/role/UseOfEstimatesAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail Use of Estimates and Summary of Significant Accounting Policies - Additional Information (Detail) Details 38 false false R39.htm 2403402 - Disclosure - Balance Sheet Account Detail - Summary of Cash and Cash Equivalents and Marketable Securities (Detail) Sheet http://sppirx.com/role/BalanceSheetAccountDetailSummaryOfCashAndCashEquivalentsAndMarketableSecuritiesDetail Balance Sheet Account Detail - Summary of Cash and Cash Equivalents and Marketable Securities (Detail) Details 39 false false R40.htm 2403403 - Disclosure - Balance Sheet Account Detail - Additional Information (Detail) Sheet http://sppirx.com/role/BalanceSheetAccountDetailAdditionalInformationDetail Balance Sheet Account Detail - Additional Information (Detail) Details 40 false false R41.htm 2403404 - Disclosure - Balance Sheet Account Detail - Schedule of Property and Equipment Net of Accumulated Depreciation (Detail) Sheet http://sppirx.com/role/BalanceSheetAccountDetailScheduleOfPropertyAndEquipmentNetOfAccumulatedDepreciationDetail Balance Sheet Account Detail - Schedule of Property and Equipment Net of Accumulated Depreciation (Detail) Details 41 false false R42.htm 2403405 - Disclosure - Balance Sheet Account Detail - Components of Inventories (Detail) Sheet http://sppirx.com/role/BalanceSheetAccountDetailComponentsOfInventoriesDetail Balance Sheet Account Detail - Components of Inventories (Detail) Details 42 false false R43.htm 2403406 - Disclosure - Balance Sheet Account Detail - Prepaid Expenses (Details) Sheet http://sppirx.com/role/BalanceSheetAccountDetailPrepaidExpensesDetails Balance Sheet Account Detail - Prepaid Expenses (Details) Details 43 false false R44.htm 2403407 - Disclosure - Balance Sheet Account Detail - Schedule of Other Receivables (Detail) Sheet http://sppirx.com/role/BalanceSheetAccountDetailScheduleOfOtherReceivablesDetail Balance Sheet Account Detail - Schedule of Other Receivables (Detail) Details 44 false false R45.htm 2403408 - Disclosure - Balance Sheet Account Detail - Components of Intangible Assets Net of Accumulated Amortization (Detail) Sheet http://sppirx.com/role/BalanceSheetAccountDetailComponentsOfIntangibleAssetsNetOfAccumulatedAmortizationDetail Balance Sheet Account Detail - Components of Intangible Assets Net of Accumulated Amortization (Detail) Details 45 false false R46.htm 2403409 - Disclosure - Balance Sheet Account Detail - Estimated Intangible Asset Amortization Expense (Detail) Sheet http://sppirx.com/role/BalanceSheetAccountDetailEstimatedIntangibleAssetAmortizationExpenseDetail Balance Sheet Account Detail - Estimated Intangible Asset Amortization Expense (Detail) Details 46 false false R47.htm 2403410 - Disclosure - Balance Sheet Account Detail - Schedule of Goodwill (Detail) Sheet http://sppirx.com/role/BalanceSheetAccountDetailScheduleOfGoodwillDetail Balance Sheet Account Detail - Schedule of Goodwill (Detail) Details 47 false false R48.htm 2403411 - Disclosure - Balance Sheet Account Detail - Summary of Other Assets (Detail) Sheet http://sppirx.com/role/BalanceSheetAccountDetailSummaryOfOtherAssetsDetail Balance Sheet Account Detail - Summary of Other Assets (Detail) Details 48 false false R49.htm 2403412 - Disclosure - Balance Sheet Account Detail - Schedule of Accounts Payable and Other Accrued Liabilities (Detail) Sheet http://sppirx.com/role/BalanceSheetAccountDetailScheduleOfAccountsPayableAndOtherAccruedLiabilitiesDetail Balance Sheet Account Detail - Schedule of Accounts Payable and Other Accrued Liabilities (Detail) Details 49 false false R50.htm 2403413 - Disclosure - Balance Sheet Account Detail - Schedule of Amounts Presented in Accounts Payable and Other Accrued Liabilities (Detail) Sheet http://sppirx.com/role/BalanceSheetAccountDetailScheduleOfAmountsPresentedInAccountsPayableAndOtherAccruedLiabilitiesDetail Balance Sheet Account Detail - Schedule of Amounts Presented in Accounts Payable and Other Accrued Liabilities (Detail) Details 50 false false R51.htm 2403414 - Disclosure - Balance Sheet Account Detail - Deferred Revenue (Details) Sheet http://sppirx.com/role/BalanceSheetAccountDetailDeferredRevenueDetails Balance Sheet Account Detail - Deferred Revenue (Details) Details 51 false false R52.htm 2403415 - Disclosure - Balance Sheet Account Detail - Summary of Other Long-Term Liabilities (Detail) Sheet http://sppirx.com/role/BalanceSheetAccountDetailSummaryOfOtherLongTermLiabilitiesDetail Balance Sheet Account Detail - Summary of Other Long-Term Liabilities (Detail) Details 52 false false R53.htm 2404402 - Disclosure - Gross-to-Net Product Sales - Reconciliation of Gross-to-Net Product Sales (Detail) Sheet http://sppirx.com/role/GrossToNetProductSalesReconciliationOfGrossToNetProductSalesDetail Gross-to-Net Product Sales - Reconciliation of Gross-to-Net Product Sales (Detail) Details 53 false false R54.htm 2405402 - Disclosure - Net Product Sales by Geographic Region and Product Line, and Composition of License Fees and Service Revenue - Schedule of Product Sales, Net by Geography (Detail) Sheet http://sppirx.com/role/NetProductSalesByGeographicRegionAndProductLineAndCompositionOfLicenseFeesAndServiceRevenueScheduleOfProductSalesNetByGeographyDetail Net Product Sales by Geographic Region and Product Line, and Composition of License Fees and Service Revenue - Schedule of Product Sales, Net by Geography (Detail) Details 54 false false R55.htm 2405403 - Disclosure - Net Product Sales by Geographic Region and Product Line, and Composition of License Fees and Service Revenue - Schedule of Product Sales, Net by Product Line (Detail) Sheet http://sppirx.com/role/NetProductSalesByGeographicRegionAndProductLineAndCompositionOfLicenseFeesAndServiceRevenueScheduleOfProductSalesNetByProductLineDetail Net Product Sales by Geographic Region and Product Line, and Composition of License Fees and Service Revenue - Schedule of Product Sales, Net by Product Line (Detail) Details 55 false false R56.htm 2405404 - Disclosure - Net Product Sales by Geographic Region and Product Line, and Composition of License Fees and Service Revenue - By Product Line (Details) Sheet http://sppirx.com/role/NetProductSalesByGeographicRegionAndProductLineAndCompositionOfLicenseFeesAndServiceRevenueByProductLineDetails Net Product Sales by Geographic Region and Product Line, and Composition of License Fees and Service Revenue - By Product Line (Details) Details http://sppirx.com/role/NetProductSalesByGeographicRegionAndProductLineAndCompositionOfLicenseFeesAndServiceRevenueTables 56 false false R57.htm 2406402 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Detail) Sheet http://sppirx.com/role/StockBasedCompensationSummaryOfStockBasedCompensationExpenseDetail Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Detail) Details 57 false false R58.htm 2407402 - Disclosure - Net Loss Per Share - Computation of Net Loss Per Share (Detail) Sheet http://sppirx.com/role/NetLossPerShareComputationOfNetLossPerShareDetail Net Loss Per Share - Computation of Net Loss Per Share (Detail) Details 58 false false R59.htm 2407403 - Disclosure - Net Loss Per Share - Schedule of Securities Excluded from Calculation of Net Loss Per Share (Detail) Sheet http://sppirx.com/role/NetLossPerShareScheduleOfSecuritiesExcludedFromCalculationOfNetLossPerShareDetail Net Loss Per Share - Schedule of Securities Excluded from Calculation of Net Loss Per Share (Detail) Details 59 false false R60.htm 2408402 - Disclosure - Fair Value Measurements - Summary of Asset and Liability Fair Values (Detail) Sheet http://sppirx.com/role/FairValueMeasurementsSummaryOfAssetAndLiabilityFairValuesDetail Fair Value Measurements - Summary of Asset and Liability Fair Values (Detail) Details 60 false false R61.htm 2408403 - Disclosure - Fair Value Measurements - Fair Value Measurement Activity for Liabilities Utilize Level 3 Inputs (Detail) Sheet http://sppirx.com/role/FairValueMeasurementsFairValueMeasurementActivityForLiabilitiesUtilizeLevel3InputsDetail Fair Value Measurements - Fair Value Measurement Activity for Liabilities Utilize Level 3 Inputs (Detail) Details 61 false false R62.htm 2409402 - Disclosure - Business Combinations and Contingent Consideration - Additional Information (Detail) Sheet http://sppirx.com/role/BusinessCombinationsAndContingentConsiderationAdditionalInformationDetail Business Combinations and Contingent Consideration - Additional Information (Detail) Details 62 false false R63.htm 2409403 - Disclosure - Business Combinations and Contingent Consideration - Change in Fair Value of Contingent Consideration Related to Acquisitions (Detail) Sheet http://sppirx.com/role/BusinessCombinationsAndContingentConsiderationChangeInFairValueOfContingentConsiderationRelatedToAcquisitionsDetail Business Combinations and Contingent Consideration - Change in Fair Value of Contingent Consideration Related to Acquisitions (Detail) Details 63 false false R64.htm 2409404 - Disclosure - Business Combinations and Contingent Consideration - Acquisition-Date Fair Value of Consideration Transferred (Detail) Sheet http://sppirx.com/role/BusinessCombinationsAndContingentConsiderationAcquisitionDateFairValueOfConsiderationTransferredDetail Business Combinations and Contingent Consideration - Acquisition-Date Fair Value of Consideration Transferred (Detail) Details 64 false false R65.htm 2409405 - Disclosure - Business Combinations and Contingent Consideration - Summary of Allocation of Total Purchase Price to Net Assets Acquired (Detail) Sheet http://sppirx.com/role/BusinessCombinationsAndContingentConsiderationSummaryOfAllocationOfTotalPurchasePriceToNetAssetsAcquiredDetail Business Combinations and Contingent Consideration - Summary of Allocation of Total Purchase Price to Net Assets Acquired (Detail) Details 65 false false R66.htm 2410402 - Disclosure - Out-License of Marqibo, Zevalin, and Evolema in China Territory to CASI - Additional Information (Detail) Sheet http://sppirx.com/role/OutLicenseOfMarqiboZevalinAndEvolemaInChinaTerritoryToCasiAdditionalInformationDetail Out-License of Marqibo, Zevalin, and Evolema in China Territory to CASI - Additional Information (Detail) Details 66 false false R67.htm 2410403 - Disclosure - Out-License of Marqibo, Zevalin, and Evolema in China Territory to CASI - Schedule of Proceeds Received and Fair Value on CASI Out-License Execution Date (Detail) Sheet http://sppirx.com/role/OutLicenseOfMarqiboZevalinAndEvolemaInChinaTerritoryToCasiScheduleOfProceedsReceivedAndFairValueOnCasiOutLicenseExecutionDateDetail Out-License of Marqibo, Zevalin, and Evolema in China Territory to CASI - Schedule of Proceeds Received and Fair Value on CASI Out-License Execution Date (Detail) Details 67 false false R68.htm 2410404 - Disclosure - Out-License of Marqibo, Zevalin, and Evolema in China Territory to CASI - Schedule of Proceeds Received and Fair Value on CASI Out-License Execution Date (Parenthetical) (Detail) Sheet http://sppirx.com/role/OutLicenseOfMarqiboZevalinAndEvolemaInChinaTerritoryToCasiScheduleOfProceedsReceivedAndFairValueOnCasiOutLicenseExecutionDateParentheticalDetail Out-License of Marqibo, Zevalin, and Evolema in China Territory to CASI - Schedule of Proceeds Received and Fair Value on CASI Out-License Execution Date (Parenthetical) (Detail) Details 68 false false R69.htm 2411402 - Disclosure - Out-License Of Zevalin In Certain Ex-U.S. Territories To Mundipharma (Details) Sheet http://sppirx.com/role/OutLicenseOfZevalinInCertainExUSTerritoriesToMundipharmaDetails Out-License Of Zevalin In Certain Ex-U.S. Territories To Mundipharma (Details) Details http://sppirx.com/role/OutLicenseOfZevalinInCertainExUSTerritoriesToMundipharma 69 false false R70.htm 2412402 - Disclosure - Out-License Of Zevalin, Folotyn, Beleodaq, And Marqibo In Canada Territory To Servier (Details) Sheet http://sppirx.com/role/OutLicenseOfZevalinFolotynBeleodaqAndMarqiboInCanadaTerritoryToServierDetails Out-License Of Zevalin, Folotyn, Beleodaq, And Marqibo In Canada Territory To Servier (Details) Details http://sppirx.com/role/OutLicenseOfZevalinFolotynBeleodaqAndMarqiboInCanadaTerritoryToServier 70 false false R71.htm 2413402 - Disclosure - Co-Promotion Arrangement With Eagle Pharmaceuticals (Details) Sheet http://sppirx.com/role/CoPromotionArrangementWithEaglePharmaceuticalsDetails Co-Promotion Arrangement With Eagle Pharmaceuticals (Details) Details http://sppirx.com/role/CoPromotionArrangementWithEaglePharmaceuticals 71 false false R72.htm 2414402 - Disclosure - Convertible Senior Notes - Additional Information (Detail) Notes http://sppirx.com/role/ConvertibleSeniorNotesAdditionalInformationDetail Convertible Senior Notes - Additional Information (Detail) Details 72 false false R73.htm 2414403 - Disclosure - Convertible Senior Notes - Carrying Value of 2018 Convertible Notes (Detail) Notes http://sppirx.com/role/ConvertibleSeniorNotesCarryingValueOf2018ConvertibleNotesDetail Convertible Senior Notes - Carrying Value of 2018 Convertible Notes (Detail) Details 73 false false R74.htm 2414404 - Disclosure - Convertible Senior Notes - Components of the Interest Expense Recognized (Detail) Notes http://sppirx.com/role/ConvertibleSeniorNotesComponentsOfInterestExpenseRecognizedDetail Convertible Senior Notes - Components of the Interest Expense Recognized (Detail) Details 74 false false R75.htm 2415402 - Disclosure - Mundipharma Agreement And Drug Development Liability - Additional Information (Detail) Sheet http://sppirx.com/role/MundipharmaAgreementAndDrugDevelopmentLiabilityAdditionalInformationDetail Mundipharma Agreement And Drug Development Liability - Additional Information (Detail) Details 75 false false R76.htm 2415403 - Disclosure - Mundipharma Agreement And Drug Development Liability - Schedule of Drug Development Liability Adjustments (Detail) Sheet http://sppirx.com/role/MundipharmaAgreementAndDrugDevelopmentLiabilityScheduleOfDrugDevelopmentLiabilityAdjustmentsDetail Mundipharma Agreement And Drug Development Liability - Schedule of Drug Development Liability Adjustments (Detail) Details 76 false false R77.htm 2416401 - Disclosure - Commitments and Contingencies - Additional Information (Detail) Sheet http://sppirx.com/role/CommitmentsAndContingenciesAdditionalInformationDetail Commitments and Contingencies - Additional Information (Detail) Details 77 false false R78.htm 2417401 - Disclosure - Income Taxes - Additional Information (Detail) Sheet http://sppirx.com/role/IncomeTaxesAdditionalInformationDetail Income Taxes - Additional Information (Detail) Details 78 false false R79.htm 2418402 - Disclosure - Stockholders' Equity (Details) Sheet http://sppirx.com/role/StockholdersEquityDetails Stockholders' Equity (Details) Details http://sppirx.com/role/StockholdersEquityTables 79 false false All Reports Book All Reports sppi-20160630.xml sppi-20160630.xsd sppi-20160630_cal.xml sppi-20160630_def.xml sppi-20160630_lab.xml sppi-20160630_pre.xml true true